Ajinomoto Co. Inc.'s Ajinomoto Bio-Pharma Services has announced a license agreement with Exelixis Inc. to incorporate AJICAP, Ajinomoto's proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' antibody-drug conjugate (ADC) programs for cancer.
A Harvard Medical School research team developed a bifunctional therapeutic vaccine strategy by transforming living tumor cells into a potent agent with direct tumor killing and immunostimulatory abilities.
Since the advent of COVID-19 mRNA vaccines, the space has steadily grown hotter, a situation on which Anima Biotech Inc. has capitalized by way of a potential $580 million-plus deal with Abbvie Inc. to deploy mRNA biology modulators for three targets across oncology and Immunology.
Hadasit Medical Research Services and Development Ltd. and BIRAD – Research & Development Company Ltd. have inked a development deal with Immix Biopharma Inc. for tissue specific therapeutics based on their jointly developed anti-B-cell maturation antigen CAR T cells targeting plasma cell technology.
Baili Biopharmaceutical Co. Ltd. has raised ¥990.47 million (US$146 million) on the Shanghai STAR Market. Its shares opened Jan. 6 at ¥28.75 apiece, surging over 30% its first trading day, and closing at ¥38.40 on Jan.9.
Wuxi Biologics (Cayman) Inc. is providing an exclusive license to GSK plc for a preclinical bispecific T-cell engaging antibody along with the option of three additional bi- and multispecific TCE antibodies developed by Wuxi. In exchange, Wuxi will receive an up-front payment of $40 million and up to $1.46 billion in additional payments for research, development, regulatory and commercial milestones across the four TCE antibodies. Wuxi Biologics, of Shanghai, is also eligible to receive tiered royalties on net sales.
Medshine Discovery Inc. has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to an androgen receptor targeting moiety via a linker acting as androgen receptor degradation inducers reported to be useful for the treatment of cancer.
Minghui Pharmaceutical (Hangzhou) Ltd. and Minghui Pharmaceutical (Shanghai) Ltd. have synthesized antibody-drug conjugates consisting of an antibody covalently linked to exatecan derivatives through a linker.
The advent of bispecific antibodies bridging two different cell types has enabled a new level of cell specificity in cancer biology that has only recently begun to be realized in the clinic.
RSS
